Brooks Laboratories Limited approves scheme to demerge manufacturing business
Key highlights
- The Board approved demerger of manufacturing business into Abridge Speciality Limited on October 14, 2026
- Post-scheme, Abridge to be renamed Brooks Laboratories Limited; Demerged company to be renamed Xuri Lifesciences Limited
- Scheme subject to approvals from Stock Exchanges, SEBI, NCLT, shareholders, and other regulators; listing expected about 16 months from filing
Why it's rated notable: the amount is 44% of market value (20% to 50%)
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 (As Amended From Time To Time)
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Brooks Laboratories
Other acquisition / merger filings this fortnight
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
- NHC Foods approves Sept 2026 quarter results, buys 99.98% of Sachmaas Foods
- Prime Fresh Limited reports Q2 & H1 FY27 revenue growth and improved margins
- Aastha Spintex completes 100% acquisition of Falcon Yarns; Q2 results approved
- Aastha Spintex completes acquisition of 100% of Falcon Yarns Private Limited
- Prestige Estates signs SPA to acquire 100% of Allure Developers Private Limited
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.